14.04

3.16% 0.43

10 X Genomics Inc (TXG)

Overview News Price History Option Chain Financials Discussions Forecast

10 X Genomics Inc stock is traded at $14.04, with a volume of 1.95M. It is up +3.16% in the last 24 hours and up +5.41% over the past month. 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Previous Close:

$13.61

Open:

$13.52

24h Volume:

1.95M

Relative Volume:

0.97

Market Cap:

$1.70B

Revenue:

$631.73M

Net Income/Loss:

$-239.78M

P/E Ratio:

-7.3508

EPS:

-1.91

Net Cash Flow:

$-33.45M

1W Performance:

-1.16%

1M Performance:

+5.41%

6M Performance:

-29.66%

1Y Performance:

-74.26%

1-Day Range:

$13.41

$14.44

1-Week Range:

$13.17

$15.31

52-Week Range:

$12.95

$57.78

10 X Genomics Inc Stock (TXG) Company Profile

Name

10 X Genomics Inc

Sector

Healthcare (1176)

Industry

Health Information Services (60)

Phone

(925) 401-7300

Address

6230 STONERIDGE MALL ROAD, PLEASANTON, CA

Employee

1,259

Twitter

@10xgenomics

Next Earnings Date

2024-10-31

Latest SEC Filings

TXG's Discussions on Twitter

Compare TXG with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TXG 10 X Genomics Inc	14.04	1.70B	631.73M	-239.78M	-33.45M	-2.02
VEEV Veeva Systems Inc	224.15	36.39B	2.66B	665.91M	1.08B	4.05
SOLV Solventum Corp	66.83	11.55B	8.26B	66.00M	1.17B	0.3682
DOCS Doximity Inc	57.83	10.80B	516.85M	174.11M	217.38M	0.87
HQY Healthequity Inc	94.95	8.23B	1.15B	96.70M	-161.99M	1.09
WAY Waystar Holding Corp	36.82	6.34B	906.14M	-52.62M	89.62M	-0.3621

10 X Genomics Inc Stock (TXG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-03-24	Initiated	Leerink Partners	Outperform
Jul-22-24	Upgrade	Jefferies	Hold → Buy
Jul-18-24	Downgrade	JP Morgan	Overweight → Neutral
Jul-10-24	Downgrade	Deutsche Bank	Buy → Hold
Jun-27-24	Downgrade	Wolfe Research	Outperform → Peer Perform
Jun-25-24	Downgrade	Guggenheim	Buy → Neutral
Jun-03-24	Resumed	Jefferies	Hold
May-01-24	Downgrade	TD Cowen	Buy → Hold
Dec-14-23	Initiated	Guggenheim	Buy
Dec-13-23	Initiated	Wolfe Research	Outperform
Dec-12-23	Upgrade	BofA Securities	Underperform → Neutral
Jul-05-23	Resumed	JP Morgan	Overweight
May-10-23	Initiated	Barclays	Overweight
Mar-31-23	Initiated	Stephens	Overweight
Feb-02-23	Initiated	UBS	Neutral
Dec-14-22	Initiated	Deutsche Bank	Buy
Aug-18-22	Downgrade	Goldman	Neutral → Sell
Jul-25-22	Initiated	Canaccord Genuity	Buy
Jul-15-22	Downgrade	BofA Securities	Neutral → Underperform
Jul-15-22	Downgrade	William Blair	Outperform → Mkt Perform
Oct-15-21	Resumed	Cowen	Outperform
Sep-14-21	Downgrade	BofA Securities	Buy → Neutral
Mar-15-21	Initiated	William Blair	Outperform
Dec-02-20	Initiated	Goldman	Neutral
Sep-09-20	Initiated	Morgan Stanley	Overweight
Jul-10-20	Initiated	Stifel	Buy
Mar-05-20	Initiated	Guggenheim	Buy
Jan-07-20	Initiated	Citigroup	Buy
Oct-07-19	Initiated	BofA/Merrill	Buy
Oct-07-19	Initiated	Cowen	Outperform
Oct-07-19	Initiated	JP Morgan	Overweight
Sep-24-19	Initiated	Evercore ISI	Outperform

View All

10 X Genomics Inc Stock (TXG) Latest News

03:31 AM

State Street Corp Has $39.53 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

03:31 AM

Dec 19, 2024

Goldman Sachs Maintains 10x Genomics Inc(TXG) Sell Recommendation - MSN

Dec 19, 2024

Dec 18, 2024

10X Genomics' SWOT analysis: genomics firm navigates challenges, eyes recovery - Investing.com

Dec 18, 2024

Dec 16, 2024

Insider Sellers Might Regret Selling 10x Genomics Shares at a Lower Price Than Current Market Value - Simply Wall St

Dec 16, 2024

Barclays PLC Has $13.61 Million Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 16, 2024

Dec 14, 2024

10X Genomics' SWOT analysis: genomics firm's stock faces instrument demand headwinds - Investing.com

Dec 14, 2024

Dec 11, 2024

10x Genomics Announces Mega-Scale Single Cell Analysis for One Cent Per Cell at Human Cell Atlas General Meeting - The Eastern Progress Online

Dec 11, 2024

XTX Topco Ltd Purchases 31,844 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 11, 2024

Dec 10, 2024

10x Genomics Reports Third Quarter 2024 Financial Results - The Eastern Progress Online

Dec 10, 2024

Dec 09, 2024

46,029 Shares in 10x Genomics, Inc. (NASDAQ:TXG) Purchased by Weiss Asset Management LP - MarketBeat

Dec 09, 2024

Dec 08, 2024

Quantinno Capital Management LP Raises Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 08, 2024

Charles Schwab Investment Management Inc. Has $14.71 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 08, 2024

Dec 07, 2024

10x Genomics (FRA:1KJ) Current Ratio : 4.90 (As of Sep. 2024) - GuruFocus.com

Dec 07, 2024

Dec 06, 2024

TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative - The Eastern Progress Online

Dec 06, 2024

Point72 Asset Management L.P. Invests $27.78 Million in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 06, 2024

Benjamin Edwards Inc. Buys 57,948 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 06, 2024

10x Genomics (STU:1KJ) Shares Outstanding (EOP) : 121.0 Mil (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (FRA:1KJ) Interest Coverage : 0 (At Loss) (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (FRA:1KJ) Shareholder Yield % : 0.42% (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (FRA:1KJ) EV-to-FCF : 68.14 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (STU:1KJ) Price-to-Operating-Cash-Flow : 50.18 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (FRA:1KJ) 3-Year Revenue Growth Rate : 21.40% (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

10x Genomics (MEX:TXG) Shares Outstanding (EOP) : 121 Mil (As of Sep. 2024) - GuruFocus.com

Dec 05, 2024

Dec 03, 2024

Cinctive Capital Management LP Takes $3.67 Million Position in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat

Dec 03, 2024

Dec 02, 2024